TG THERAPEUTICS, INC. (TGTX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TGTX currently has 161M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 2.33% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 05, 2025 |
10-Q filing | 161.0M shares outstanding |
160M | 0 |
| Aug 08, 2025 |
10-Q filing | 162.6M shares outstanding |
160M | 0 |
| May 09, 2025 |
10-Q filing | 162.8M shares outstanding |
160M | 0 |
| Mar 03, 2025 |
10-K filing | 160.3M shares outstanding |
160M | 0 |
| Nov 07, 2024 |
10-Q filing | 160.7M shares outstanding |
160M | 0 |
| Aug 09, 2024 |
10-Q filing | 159.4M shares outstanding |
160M | 0 |
| May 06, 2024 |
10-Q filing | 146.2M shares outstanding |
150M | 0 |
| Feb 29, 2024 |
10-K filing | 148.5M shares outstanding |
150M | 0 |
| Jan 10, 2024 |
8-K filing: TG Therapeutics, Inc. entered into a License Agreement with Precision BioSciences, Inc., involving an equity investment by TG Therapeutics in Precision's common stock. ($2.25M proceeds) |
160M | 0 |
| Nov 06, 2023 |
10-Q filing | 155.9M shares outstanding |
160M | 0 |
| Aug 04, 2023 |
10-Q filing | 141.5M shares outstanding |
140M | 0 |
| May 08, 2023 |
10-Q filing | 140.3M shares outstanding |
140M | 0 |
| Mar 01, 2023 |
10-K filing | 135.4M shares outstanding |
140M | 0 |
| Nov 09, 2022 |
10-Q filing | 135.3M shares outstanding |
140M | 0 |
| Aug 09, 2022 |
10-Q filing | 134.8M shares outstanding |
130M | 0 |
| May 10, 2022 |
10-Q filing | 134.4M shares outstanding |
130M | 0 |
| Mar 01, 2022 |
10-K filing | 142.8M shares outstanding |
140M | 0 |
| Jan 04, 2022 |
8-K filing: TG Therapeutics Inc. entered into an Amended and Restated Loan and Security Agreement with Hercules Capital, Inc., increasing the loan amount to $200 million and issuing a warrant to purchase 115,042 shares of common stock at an exercise price of $17.95. |
140M | 0 |
| Nov 08, 2021 |
10-Q filing | 142.9M shares outstanding |
140M | 0 |
| Aug 06, 2021 |
10-Q filing | 142.8M shares outstanding |
140M | 0 |
| May 10, 2021 |
10-Q filing | 141.5M shares outstanding |
140M | 0 |
| Mar 01, 2021 |
10-K filing | 140.6M shares outstanding |
140M | 0 |
| Dec 16, 2020 |
8-K filing: TG Therapeutics, Inc. entered into an underwriting agreement to sell 6,320,000 shares of common stock, with underwriters exercising their option to purchase an additional 948,000 shares, resulting in gross proceeds of approximately $316 million before deductions. ($316.0M proceeds) |
130M | 0 |
| Nov 09, 2020 |
10-Q filing | 131.5M shares outstanding |
130M | 0 |
| Aug 10, 2020 |
10-Q filing | 126.6M shares outstanding |
130M | 0 |
| May 18, 2020 |
8-K filing: TG Therapeutics, Inc. completed a public offering of 9,775,000 shares of common stock at an expected gross proceeds of approximately $176 million. ($176.0M proceeds) |
110M | 0 |
| May 11, 2020 |
10-Q filing | 113.7M shares outstanding |
110M | 0 |
| Mar 02, 2020 |
10-K filing | 109.4M shares outstanding |
110M | 0 |